ClinicalTrials.gg
RecruitingNCT07315958ALSACUpdated Sep 21, 2026

Study for Assessing the Prevalence of Airflow Limitation in Outpatients With History of Smoking Attending Cardiology Clinics

An observational study in Respiratory (Chronic Obstructive Pulmonary Disease), sponsored by AstraZeneca. Recruiting at 2 sites in Turkey (Türkiye). Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by AstraZeneca · Observational

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
1,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.

Planned enrollment
44th of 89
1,000 · median 976
Started
2025
with 12 others
Observational
90 of 284
7 open now
Primary completion
2027-04
later than 2 of 14 live
Registered
282nd of 284
by date

Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 44th largest by planned enrollment of the 89 observational ones that give a count, is one of 13 that started in 2025, is one of 90 observational ones, reaches primary completion later than 2 of the 14 other live ones, and was the 282nd registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, or all of them as a file.
02

Study summary

Chronic Obstructive Pulmonary Disease (COPD) is a global health concern, associated with structural lung abnormalities causing persistent airflow limitation (AL) and often result from cigarette smoking. In Turkey, COPD was ranked the third among the mortality causes and the eighth among disability causes, with 9.1% to 19.1% prevalence rate. In the Middle East and North Africa (MENA) region, an increase of 30.6% in age-standardized point prevalence occurred between 1990 and 2019, with an estimated 10.7 million COPD cases. Similarly, in the sub-Saharan Africa region, the highest COPD prevalence rate of 24.8% was observed in South Africa. And in Kenya, East Africa, the pooled point estimate prevalence of COPD was 11.3%. The prevalence of COPD varies substantially between countries, but comparing numbers is challenging because they are recorded in different units and during different periods.

Patients with COPD are more likely to develop cardiovascular disease (CVD). For instance, COPD has been shown to increase the risk of acute myocardial infarction by 40% and stroke by 50%. Likewise, COPD patients with CVD have a considerably higher risk of COPD exacerbations than those without CVD. COPD and CVD have been linked to a worse prognosis primarily related to increased systemic inflammation; the presence of a concomitant disease with COPD leads to reduced quality of life, increased hospitalizations, and worse survival. For instance, every increase of 70 cL/s in forced expiratory volume in 1 second (FEV1) reduces mortality risk by 28%-35% from cardiovascular disease and 68%-72% from respiratory disease. Besides that, smoking has been shown to increase the risk of myocardial infarction (MI) and heart failure (HF) twofold, cigarette smoking toxins promote inflammation systemically, which may result in emphysema and atherosclerosis. Nevertheless, chronic inhalation of irritants, including biomass fuel smoke and air pollutants, produces an innate immune response and a later activation of adaptive immunity that might further amplify inflammation. Similarly, age-related elastin degradation may increase the risk of emphysema and arterial hypertension. On the contrary, physical activity is associated with improved lung function and a lower resting heart rate (RHR); consequently, COPD and CVD are more prevalent in sedentary populations. Observational studies suggest that decreasing the progression of COPD may assist in preventing cardiovascular morbidity and mortality, which is related to more severe respiratory symptoms.

03

Conditions studied

  • Respiratory (Chronic Obstructive Pulmonary Disease)

Keywords

  • chronic obstructive pulmonary disease
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients attending cardiology clinics for any reason:

  1. Patients aged 40 years or older.
  2. Patients with a smoking history of 10 pack-years or more.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged 40 years or older.
  2. Patients with a smoking history of 10 pack-years or more.
  3. Patients willing and able to complete pulmonary function test, using a spirometer.
  4. Patients who have provided written consent to participate in the study.
  5. Patients attending cardiology clinics at the participating centers.
  6. Patients willing and able to complete the CAAT questionnaire.

Exclusion criteria

Exclusion Criteria:

A. Patients diagnosed with bronchial asthma. B. Patients who used a bronchodilator for an acute respiratory infection before performing spirometry.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
1,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Prevalence (number and percentage) of outpatients attending cardiology clinics, with a history of smoking who exhibit concurrent AL consistent with COPD.

    Prevalence (number and percentage) of outpatients attending cardiology clinics, with a history of smoking who exhibit concurrent AL consistent with COPD.

    Time frame: 1 Year

Secondary outcomes

  1. The proportion of patients with CVD who were previously diagnosed with COPD.

    The proportion of patients with CVD who were previously diagnosed with COPD.

    Time frame: 1 Year

  2. The distribution of patients with AL consistent with COPD among AL severity GOLD grades 1-4.

    The distribution of patients with AL consistent with COPD among AL severity GOLD grades 1-4. GOLD 1 = MILD GOLD 2 = Moderate GOLD 3 = Severe GOLD 4 = Very Severe

    Time frame: 1 Year

  3. CAAT score of patients with AL consistent with COPD.

    CAAT score of patients with AL consistent with COPD. 10-20: Medium impact on daily life. 20-30: High impact. \>30: Very high impact.

    Time frame: 1 Year

  4. The severity of COPD

    The severity of COPD using GOLD ABE assessment scheme. Group A: Low Risk, Low Symptoms Group B: Low Risk, High Symptoms Group E: High Risk

    Time frame: 1 year

07

Study locations

2 of 2 sites recruiting
  • Research Site
    Ankara, Turkey (Türkiye)
    Recruiting
  • Research Site
    Istanbul, Turkey (Türkiye)
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Apr 2027, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2025
First posted
Jan 5, 2026
StartActual
Oct 8, 2025
Primary completionEst.
Apr 30, 2027
CompletionEst.
Apr 30, 2027
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07315958
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jan 5, 2026
Start date
Oct 8, 2025
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Sep 21, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion